Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
1st June 2026 Uncategorised 0After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the prevention setting.
More: Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative
Source: fierce